Atopic DermatitisFeatured PodcastPodcast Highlights

AD Treatment – The Future Landscape

By April 13, 2021August 23rd, 2022No Comments

JDD Multimedia

Love28

JDD Podcast

Listen Now

Play Video

How to Listen

AD Treatment – The Future Landscape

Drs. Amy Paller, Jonathan Silverberg & Adam Friedman

 

Consider this final episode of the 5 part all you can handle Atopic Dermatitis series the world series of dermatitis. Hall of famers Dr.s Amy Paller and Jonathan Silverberg join host Dr. Adam Friedman to review current moderate to severe AD treatment approaches and use of systemic therapies, discuss advancement on AD clinical management with use of novel target therapy, and share clinical experience with the use of biologics treatment. As we have all been thrown a curve ball in life, faculty address the growing concerns surrounding dermatology-related immunosuppressant therapy during the pandemic and how to discuss this issue with patients. Slide into home with a peak at the future therapies landscape in clinical development. The practical peals alone are worth the price of admission (um, it’s free).
Listen Now
Learning Objectives
Upon completion of this podcast participants should be able to:
  • Recognize the impact of target therapeutic in managing moderate to severe AD
  • Consider future treatment strategies that may enhance optimal patient care

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

Disclosures
Amy Paller, MD – Grant/Research Support: AbbVie, Eli Lilly, Regeneron. Incyte. Consultant: Abbvie, Arena, Bausch, Bristol Myer Squibb, Dermavant, Eli Lilly, Forte, Leo, Lifemax, Pfizer, Rapt, Regeneron, and Sanofi.

Jonathan Silverberg, MD – Grant/Research Support: Galderma, Pfizer. Consultant: Abbvie, Afyx, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi. Speakers’ Bureau: Regeneron, Sanofi-Genzyme, Pfizer, Eli Lilly.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.

You May Also Like

From Rags to Itches: The Evolution of Topical and Systemic Options for Pruritus

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Life's an itch sometimes….am I right? Pruritus can pick apart the fabric of one's life as both a symptom of a primary skin disease or even as a…
Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array of nonsteroidal options, understanding the underpinnings to both use them for their intended purpose, but even more fun, OOOOOOFFFFFF LLLLLLAAAAABBBBEEEELLLL (clearly a fan of off label), is paramount to patient outcomes. Be not overwhelmed I say, as the bench to bedside badass Dr. Christopher Bunick is here for all your on and off label needs. Take a break from the typical Tuesday with a topical translational deep dive into the tantalizing options as host Dr. Adam Friedman tees off with Dr. Bunick for what is certain to be a “tough” (as the kids say) podcast.

Touching on Tailored Topical for Tons of Tough Treatment Tchallenges

| Featured Articles, Featured Podcast, Podcast Highlights, The Latest | No Comments
Featured Podcast Even in a world of exponentially expanding systemic options both on and off label, one fact remains: topical therapy is ALWAYS on the menu. With an unprecedented array…
What a time to be a psoriasis patient, decades into the golden age of management strategies. With an embarrassment of treatment riches, all patients are clear right? Slow your roll you say? The paradigm shift has occurred and for many of our established patients it’s now about cleaning up the biologic leftovers, especially when located on far reaching and sensitive sites. How to do so? So glad you asked, as we are so fortunate Dr. Peter Lio, clinical assistant professor of dermatology and pediatrics at Northwestern, joined host Dr. Adam Friedman to provide his experiences to pick apart the NYC diner menu of topical option add-ons to our powerful buffet of advanced systemics. Make sure to come hungry!

Pspecial Psite Psoriasis Pearls: Picking the Right Combo Meal for your Patients

| Featured Articles, Featured Podcast, Podcast Highlights, Psoriasis, The Latest | No Comments
Featured Podcast What a time to be a psoriasis patient, decades into the golden age of management strategies. With an embarrassment of treatment riches, all patients are clear right? Slow…

Tags:

Leave a Reply

Close Menu